8-K: Kintara Therapeutics Provides Update on Merger and Clinical Trial Progress

Kintara Therapeutics is urging shareholders to vote in favor of a proposed merger with TuHURA Biosciences, while also providing an update on their REM-001 clinical study.

Summary

• Kintara Therapeutics and TuHURA Biosciences have a definitive merger agreement in place, where TuHURA will become a wholly-owned subsidiary of Kintara.
• Kintara's existing stockholders will own approximately 5.45% of the combined company's common stock after the merger, on a pro forma fully diluted basis.
• Stockholders will also receive contingent value rights (CVRs) for additional shares upon the REM-001 study enrolling a minimum of 10 patients who complete 8 weeks of follow-up by December 31, 2025.
• A special meeting of stockholders is scheduled for September 20, 2024, to vote on the merger.
• The REM-001 clinical study for cutaneous metastatic breast cancer has enrolled four of the required ten patients to assess safety and determine the appropriate Phase 3 dose.
• No treatment-related safety issues have been identified in the REM-001 study to date.
• The majority of the REM-001 study costs are covered by a $2.0 million SBIR grant from the National Institutes of Health.
• Without the merger, Kintara may not have sufficient funds to continue the REM-001 study or operate its business and may need to seek bankruptcy protection.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the company's financial instability and reliance on the merger to avoid bankruptcy. While there is positive progress in the clinical trial, the overall situation is precarious.

Positives

• The REM-001 study has shown no treatment-related safety issues to date.
• The REM-001 study is addressing an unmet medical need in cutaneous metastatic breast cancer.
• A $2.0 million grant is covering the majority of the REM-001 study costs.
• The merger with TuHURA could provide the necessary financial resources for Kintara to continue operations and the REM-001 study.

Negatives

• Kintara's existing stockholders will have a significantly reduced ownership stake of approximately 5.45% in the combined company.
• The merger is contingent on a minimum of 10 patients completing 8 weeks of follow-up in the REM-001 study by December 31, 2025, which introduces uncertainty.
• Kintara may not have adequate financial resources to continue the REM-001 study or operate its business without the merger.
• The company may be required to seek bankruptcy protection if the merger does not proceed.

Risks

• The merger is subject to stockholder approval and may not be completed.
• There are uncertainties regarding the timing of the merger and the ability of both companies to complete the transaction.
• Delays in the merger could impact the combined company's cash resources.
• The REM-001 study may not achieve the required milestone of enrolling 10 patients who complete 8 weeks of follow-up by December 31, 2025.
• The combined company's business may not be successful.
• There are risks associated with estimating operating expenses and merger-related costs.
• Legal proceedings related to the merger could arise.
• The company's intellectual property rights may not be adequately protected.
• The company faces competitive responses to the merger.

Future Outlook

The company's future is heavily dependent on the successful completion of the merger with TuHURA, which is needed to secure funding for continued operations and the REM-001 clinical study. The company is also relying on the REM-001 study achieving the milestone of enrolling 10 patients who complete 8 weeks of follow-up by December 31, 2025.

Management Comments

• Kintara stockholders are urged to vote their shares before the Special Meeting on September 20, 2024.
• The suspension of Kintara's clinical trial would have an adverse effect on the progress that is being made in the study.
• Please support the clinical advancements Kintara is looking to make in the lives of breast cancer patients.

Industry Context

The merger is occurring in the context of the biopharmaceutical industry where companies often merge to consolidate resources and expertise. The REM-001 study is focused on a specific unmet need in cancer treatment, which is a common area of focus for biopharmaceutical companies.

Comparison to Industry Standards

• The REM-001 study is targeting cutaneous metastatic breast cancer, a niche area with limited treatment options, which is similar to other companies focusing on rare or difficult-to-treat cancers.
• The use of a Small Business Innovation Research (SBIR) grant to fund the REM-001 study is a common practice for smaller biotech companies seeking non-dilutive funding.
• The merger structure, where one company becomes a wholly-owned subsidiary of another, is a standard approach in the industry for consolidating operations and resources.
• The contingent value rights (CVRs) are a mechanism used in mergers to provide additional value to shareholders based on the achievement of specific milestones, which is a common practice in the biotech sector.

Stakeholder Impact

• Shareholders face significant dilution of their ownership stake in the combined company.
• Employees' jobs are at risk if the merger does not proceed and the company faces bankruptcy.
• Patients with cutaneous metastatic breast cancer may lose access to a potential treatment option if the REM-001 study is halted.
• Creditors face the risk of not being repaid if the company enters bankruptcy.

Next Steps

• Kintara stockholders need to vote on the proposed merger by September 19, 2024.
• The Special Meeting of Stockholders will be held on September 20, 2024.
• The REM-001 study needs to enroll a minimum of 10 patients who complete 8 weeks of follow-up by December 31, 2025, to trigger the CVRs.
• The merger with TuHURA needs to be completed to secure the company's financial future.

Key Dates

Keywords

Merger, Kintara Therapeutics, TuHURA Biosciences, REM-001, Clinical Study, Cutaneous Metastatic Breast Cancer, Stockholders, Contingent Value Rights, Bankruptcy, SBIR Grant